Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages 137-140 , March 2008

Clinical Applications of Positron Emission Tomography/Computed Tomography Treatment Planning

  • Homer A. Macapinlac, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Homer A. Macapinlac, MD, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  2. Verboom P, Van Tinteren H, Hoekstra OS, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging. 2003;30:1444–1449
  3. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  4. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al. FDG-PET in staging lung cancer: How does it change the algorithm?. Lung Cancer. 2004;44:175–181
  5. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–1951
  6. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in nonsmall-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph nodestations from 68 patients. J Clin Oncol. 1998;16:2142–2149
  7. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–261
  8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol. 2004;22:330–353
  9. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526–533
  10. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer. 2007;110:2155–2168
  11. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006;130:710–718
  12. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings. Am J Clin Oncol. 1996;19:416–421
  13. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluro-seoxyglucose positron emission tomography imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167–177
  14. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomograpy (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  15. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects. Lung Cancer. 1999;23:105–114
  16. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  17. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51–60
  18. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–863
  19. Greco C, Rosenzweig K, Cascini GL, et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer. 2007;57:125–134
  20. Erdi YE, Rosenweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51–60
  21. Erdi Y, Mawlawi O, Imbriaco M, et al. Volume determination for metastatic lung lesions by adaptive PET image thresholding. Cancer. 1997;80:2505–2509
  22. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78–86
  23. Biehl KJ, Kong FM, Dehdashti F. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: Is a single standardized uptake value threshold approach appropriate?. J Nucl Med. 2006;47:1808–1812
  24. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002;43:876–881
  25. Pan T, Mawlawi O, Nemeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;46:1481–1487
  26. Pan T, Mawlawi O, Luo D, et al. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys. 2006;33:3931–3938
  27. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005;49:95–108
  28. Klopp AH, Chang JY, Tucker SL, et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007;69:1409–1416
  29. Faria SL, Menard S, Devic S, et al: Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys, in press
  30. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  31. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Mol Imaging Biol. 2006;8:141–150
  32. Yamamoto Y, Nishiyama Y, Kimura N, et al: Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, in press
  33. Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of (18)F-FLT and (18)F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610–1616
  34. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981;41:73–81
  35. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA. 1986;83:5978–5982
  36. Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51
  37. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  38. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med. 2001;45:183–188
  39. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  40. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  41. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850

PII: S0001-2998(07)00143-2

doi: 10.1053/j.semnuclmed.2007.11.005

Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages 137-140 , March 2008

Article Tools